Biofrontera AG: Biofrontera announces preliminary unaudited sales revenues for the 1st Quarter 2018
Biofrontera announces preliminary unaudited sales revenues for the 1st Quarter 2018
Leverkusen, Germany, 12 April 2018 - Biofrontera AG (NASDAQ ticker symbol: BFRA, ISIN: DE0006046113), the specialist for the treatment of sun-induced skin cancer, today announced preliminary unaudited revenue for the first quarter of fiscal year 2018.
The preliminary unaudited revenues of Biofrontera group for the period January to March 2018 were between 4.6 and 4.7 million euros. This corresponds to a sales growth of approx. 80% compared to the previous year, with pure product sales increasing by approximately 107%.
Preliminary unaudited quarterly product sales in the USA are expected to be approximately EUR 3.4 million, compared to EUR 1.3 million in the same period in 2017; product sales in Germany and Europe will be approximately EUR 1.2 million, compared to EUR 0.9 million in Q1 2017.
Overall, sales in the first quarter of 2018 were thus significantly higher than in the previous year and are further proof of the company's successful growth strategy.
Biofrontera AG, Hemmelrather Weg 201, 51377 Leverkusen ISIN: DE0006046113 WKN: 604611
Contact: Biofrontera AG Tel.: +49 (0214) 87 63 2 0, Fax.: +49 (0214) 87 63 290 E-mail: email@example.com
12-Apr-2018 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.deLanguage: English Company: Biofrontera AG Hemmelrather Weg 201 51377 Leverkusen
Germany Phone: +49 (0)214 87632 0 Fax: +49 (0)214 87632 90 E-mail: firstname.lastname@example.org Internet: www.biofrontera.com ISIN: DE0006046113, NASDAQ: BFRA WKN: 604611 Listed: Regulated Market in Dusseldorf, Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Hamburg, Munich, Stuttgart, Tradegate Exchange; Nasdaq End of Announcement DGAP News Service
674013 12-Apr-2018 CET/CEST